Respiratory Infection Detection via Cytokine Panel Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for respiratory viruses are unable to detect emerging viral pathogens and cannot distinguish between viral-only and bacterial-associated respiratory infections, leading to inadequate preparation for epidemic viral outbreaks and inappropriate antibiotic use.
Innovation Solution
A method involving the analysis of respiratory samples to determine levels of specific viral and bacterial infection-associated molecules, such as CXCL10, CCL2, IL-10, IL-8, TNF, and IL-1β, compared to predetermined reference levels to differentiate between viral and bacterial respiratory infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If specific tests are performed for each viral or bacterial infection, then detection accuracy is improved, but test cost becomes prohibitive
Solution Approach 1:
The patent applies a universal panel of 12 cytokines that can detect both viral and bacterial respiratory infections through a single multi-purpose test. This multi-functional approach replaces the need for multiple separate specific tests, achieving broad detection capability across different pathogen types while controlling costs through consolidation.
Solution Approach 2:
The patent shifts the detection parameter from direct pathogen identification to measurement of host immune response markers (cytokines). By detecting the body's immune response pattern rather than the pathogen itself, the test achieves high accuracy for both viral and bacterial infections using a standardized panel, improving cost-efficiency.
2Reliability
If current diagnostic tests are used, then known viruses can be detected, but emerging viral pathogens cannot be detected
Solution Approach 1:
The patent performs preliminary detection of immune response markers before specific pathogen identification is attempted. By measuring cytokine levels first, the system can identify emerging pathogens that have triggered immune responses even before their genetic sequences are known or before specific tests are designed, enabling early detection of novel viruses.
Solution Approach 2:
The patent uses host immune response markers (cytokines) as intermediary indicators to indirectly detect both known and emerging pathogens. This intermediary approach allows the system to detect pathogen presence through the body's immune reaction rather than requiring direct pathogen detection, thereby expanding detection scope to include emerging viruses.
3Measurement precision
If viral infection tests are performed, then viral infections can be detected, but bacterial infections cannot be distinguished
Solution Approach 1:
The patent segments the 12-cytokine panel into viral-associated cytokines and bacterial-associated cytokines, allowing the system to distinguish between viral-only, bacterial-only, and co-infection scenarios. This segmentation enables precise differentiation of infection types by analyzing which subset of cytokines is elevated, preventing loss of infection differentiation information.
Solution Approach 2:
The patent applies local quality analysis by examining which specific cytokines within the panel are elevated. Different patterns of cytokine elevation (e.g., interferon-rich patterns for viral vs. neutrophil-rich patterns for bacterial) provide localized diagnostic information that enables accurate distinction between infection types while maintaining comprehensive detection capability.
Data Source
AI summary
In one aspect, the invention provides a method for detecting a viral-only or a bacterial-associated respiratory infection in a patient, the method comprising analyzing a respiratory sample to determine levels of at least two respiratory virus infection-associated molecules, at least two bacterial respiratory infection-associated molecules, and comparing the levels of the respiratory virus infection-associated molecules and/or the levels of the bacterial respiratory infection-associated molecules with a predetermined reference level.